Last reviewed · How we verify
NCT05957848: GRACE
Guanfacine Extended-release for Adolescents With Cannabis Use
Phase 2 trial testing Guanfacine Extended Release Oral Tablet in Cannabis Use Disorder in 100 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | Orygen |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 27 July 2023 |
| Primary completion | 31 December 2025 |
| Estimated completion | 30 June 2026 |
| Sites | 1 location across Australia |
Drugs / interventions tested
- Guanfacine Extended Release Oral Tablet
- Residential withdrawal
- Engagement with alcohol and other drug services
- Placebo
Conditions studied
- Cannabis Use Disorder — all drugs for Cannabis Use Disorder →
Sponsor
Orygen
Who can join
Adults 12 to 25, any sex, with Cannabis Use Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A randomized controlled trial to assess the efficacy of extended-release guanfacine to reduce cannabis use frequency in young people with cannabis use disorder following a period of monitored abstinence.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05957848
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Guanfacine Extended Release Oral Tablet
Trials testing the same drug.
- NCT03333668 — Experimental fMRI Study of Guanfacine and Lisdexamfetamine in ADHD Adolescents · NA · unknown
Other recruiting trials for Cannabis Use Disorder
Currently open trials in the same condition.
- NCT07523633 — Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder · Phase 2 · recruiting
- NCT07056894 — Effects of Action-Based Cognitive Remediation on Substance Misuse in Early Phase Psychosis · NA · recruiting
- NCT07218471 — Cannabis Reduction and Functional Outcomes · NA · recruiting
- NCT07184983 — RS-tDCS for Cannabis Use Disorder: The C.A.R.E.S. Initiative · NA · recruiting
- NCT06883162 — Cannabis-Tobacco Co-Use Treatment Study · Phase 3 · recruiting
Other Orygen trials
Trials by the same sponsor.
- NCT06894836 — Hybrid Type 2 Implementation-Effectiveness Trial of a Third Wave Virtual Reality Treatment for Youth Depression/Anxiety · Phase 2 · not yet recruiting
- NCT06463470 — Cognitive Behavioural Therapy for Avoidant/Restrictive Food Intake Disorder (CBT-AR) · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05957848 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Orygen
- Last refreshed: 31 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05957848.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing